SCHEMBL10255409

SCHEMBL10255409

CCN1CCN(c2cncc(-c3nnc(-c4ccc(CNC)cc4)o3)n2)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATR Q13535 8/20 0.42
HSD17B10 Q99714 2/20 0.39
KMT2A Q03164 2/20 0.39
KDM4E B2RXH2 2/20 0.39
ALDH1A1 P00352 2/20 0.39
MAPT P10636 2/20 0.38
MEN1 O00255 1/20 0.38
USP2 O75604 1/20 0.38
HPGD P15428 1/20 0.38
TSHR P16473 1/20 0.38
PIM1 P11309 2/20 0.36
PIM3 Q86V86 2/20 0.36
PIM2 Q9P1W9 2/20 0.36
RAD52 P43351 1/20 0.36
NTRK1 P04629 1/20 0.36
KIT P10721 1/20 0.36
SRC P12931 1/20 0.36
FLT3 P36888 1/20 0.36
CYP11B1 P15538 1/20 0.35
CYP11B2 P19099 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10256015 0.90 PIM2 (0.44) ATRHSD17B10KDM4EALDH1A1MAPT
SCHEMBL10255565 0.87 ATR (0.41) ATRKMT2AKDM4EALDH1A1MAPT
SCHEMBL10255566 0.85 CKS1B (0.41) ATRHSD17B10KMT2AKDM4EALDH1A1
SCHEMBL10256060 0.82 CLK2 (0.40) ATRPIM1PIM3PIM2PARP1
SCHEMBL616505 0.81 ATR (0.56) ATR
SCHEMBL10255478 0.80 ATR (0.41) ATRKMT2ACYP11B2
SCHEMBL10255483 0.80 ATR (0.38) ATRMAPTPIM1PIM3PIM2
SCHEMBL10256012 0.80 ATR (0.38) ATRKMT2AKDM4EMEN1TSHR
SCHEMBL10255403 0.79 NPC1 (0.38) ATRKMT2AALDH1A1MAPTMEN1
SCHEMBL10256054 0.79 ATR (0.38) ATRPIM1PIM3PIM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8410112-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-04-02 US disclosed
US-20120040020-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040020-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, CHEK2, CHEK1 ATR 1/4885HSD17B10 3987/4885KMT2A 2291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.